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AbstractmAs a dose-response relationship has been sug-
gested for cisplatin, it appeared attractive to explore high-
dose-intensity regimens in non-small-cell lung cancer. In a
phase I study of weekly administration of cisplatin com-
bined with oral etoposide we achieved a cisplatin dose
intensity of 52.5– 60 mg/m2 per week in most patients. We
subsequently explored this regimen in advanced non-small-
cell lung cancer. Patients were treated with cisplatin infused
at 70 mg/m2 on days 1, 8, 15 and 29, 36, 43 in combination
with oral etoposide given at 50 mg on days 1– 15 and
29– 43. Patients showing stable disease or a better response
were continued on treatment with oral etoposide given at
50 mg/m2 per day on days 1 – 21 every 28 days for a
maximum of four cycles. In all, 22 patients with stage III
disease and 31 patients with stage IV disease entered the
study. The median number of cisplatin administration was 6
per patient; 17 patients reached the planned cisplatin dose
intensity of 60 mg/m2 per week, 11 patients achieved
52.5 mg/m2 per week, and 7 patients reached 47 mg/m2
per week. Overall, 11 of 21 stage III patients had a partial
response [response rate 51%, 95% confidence interval (CI)
36– 81%], as did 9 of 28 patients with stage IV disease
(32%; 95% CI 15 –49%). Toxicity was mainly hematologic,
with leukocytopenia being the most frequent cause of
treatment delay. Nephrotoxicity of grade 1 was observed
in seven patients. Two patients developed clinical hearing
loss. With this schedule a high median cisplatin dose
intensity of 52.5– 60 mg/m2 per week was reached. The
51% response rate achieved in stage III disease makes this
schedule attractive for further exploration; however, it is
not recommended for routine use in stage IV disease.
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Introduction
The prognosis for patients with locally advanced or meta-
static non-small-cell lung cancer (NSCLC) remains poor in
spite of the continuous exploration of new cytotoxic drugs
and the introduction of combined modality regimens. The
impact of cisplatin-containing chemotherapy on survival is
modest [29, 36, 38]. The meta-analysis of Donnadieu et al.
[9] has shown that the response rate obtained with combi-
nations of cisplatin with podophyllotoxins, vinca alkaloids,
or ifosfamide and mitomycin C averages 34% in stage III
disease but only 22% in metastatic disease. The combina-
tion of cisplatin and etoposide is widely used in NSCLC.
Both drugs have only limited single-agent activity, with
response rates varying from 8% to 30% [1 –4, 7, 10, 11, 28,
32, 35, 40]. The combination is suggested to be synergistic
in cell lines as well as clinically [25, 37]. The activity and
side effects of commonly applied schedules of this combi-
nation have been extensively described [22].
In several tumor types a relationship has been suggested
between the cisplatin dose intensity and the response rate or
response duration [12, 13, 16, 31]. However, the results of
prospective randomized studies addressing the issue of
cisplatin dose intensity in NSCLC have not been conclusive
[14, 16, 23]. The highest cisplatin dose intensity reached in
these studies was 41 mg/m2 per week [14].
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In a phase I study exploring weekly administration of
cisplatin combined with oral etoposide, we reached a higher
median cisplatin dose intensity of 52.5 mg/m2 per week
[33]. In this schedule we made use of oral etoposide since
its long-term administration is feasible and its activity has
been demonstrated in various tumors, including NSCLC
[17, 41]. The results of the present phase II study of this




Patients with histologically proven NSCLC of locally advanced disease
stage III a or IIIb [26] or with distant metastases were entered in this
study. Further eligibility criteria included a measurable lesion, a WHO
performance status of 2 or better, a WBC of 43.0 · 109/l, a platelet
count of 4100 · 109/l, creatinine clearance of 460 ml/min, and a
serum bilirubin level of 525 m mol/l. Before the start of the treatment
all patients had a full medical history and physical examination an
ECG, a chest X-ray, computerized tomography (CT) of the chest and
upper abdomen with and without i. v. contrast, and, if appropriate,
clinical measurement of pathological lymph nodes or skin metastases.
All patients underwent a neurological examination before the start of
and after the completion of the cisplatin treatment and every 3 months
thereafter.
During treatment, patients underwent a weekly physical examina-
tion; assessment of toxicity; full blood counts; determination of serum
electrolyte, calcium, magnesium, and creatinine levels; liver-function
tests; and determination of creatinine clearance. The response to
treatment was assessed at 2 weeks after the last cisplatin administra-
tion. Standard WHO criteria were used for evaluation of response and
toxicity [42].
Treatment schedule
Cisplatin was infused at a dose of 70 mg/m2 on days 1, 8, 15, and days
29, 36 and 43. Oral etoposide was given at a dose of 50 mg daily on
days 1–15 and 29–43. During the cisplatin administration, patients
were hospitalized for 24 h. The treatment regimen consisted of
prehydration with 1000 ml dextrose-saline + 20 mmol KCL + 1 g
MgSO4 over 4 h. Cisplatin powder was dissolved in 250 ml 3% NaCl
and infused over 3 h, after which posthydration with 2 l dextrose-saline
+ 40 mmol KCl + 2 g MgSO4 was carried out over 8 h. As an
antiemetic regimen, 8 mg ondansetron + 10 mg dexamethasone was
given as a slow i. v. bolus directly before the start of the cisplatin
infusion, and this treatment was repeated if necessary after 12 h. For
delayed nausea and vomiting, metoclopramide was given at 20 mg
t. i. d. orally or per suppository. Dose reductions were not allowed. If at
the day of planned cisplatin administration the WBC was 52.5 · 109/l
and/or the platelet count was 575 · 109/l, treatment was postponed
until recovery to levels above these values, with the maximal delay
being 2 weeks. In the case of a delay of 42 weeks or in the case of
development of neuro- or nephrotoxicity of grade 2, patients had to be
taken off study.
Patients responding to the treatment or showing stable disease at
the first response evaluation were continued on treatment with oral
etoposide at a dose of 50 mg/m2 on days 1–21 every 28 days for a
maximum of four cycles. Etoposide was given as 50-mg soft gelatin
capsules, and the dose was adjusted such that the dose delivered per
treatment cycle deviated 55% from the planned dose. During the
treatment with oral etoposide, patients underwent full blood counts
every 2 weeks and determination of serum electrolytes as well as liver-
and renal-function tests every 4 weeks. Tumor response was evaluated
every 8 weeks.
Results
A total of 54 patients were registered in the study. One
patient was considered ineligible because of small-cell
histology. Three patients were considered nonevaluable
for response: one patient never started treatment, one
patient had a protocol violation (too low a cisplatin dose),
and one patient had concomitant radiotherapy on the
indicator lesion. In all, 15 patients did not complete the
planned treatment: 6 patients developed progressive dis-
ease, 2 patients had a treatment delay of 42 weeks due to
leukocytopenia, 2 patients refused further treatment (1 after
the first and 1 after the fourth cisplatin administration), 1
patient died of a myocardial infarction, 1 patient was taken
off study because of the development of tinnitus after the
second cisplatin cycle, 1 patient developed neutropenic
fever, 1 patient had erysipelas, and 1 patient developed
reversible cortical blindness after the fifth cisplatin cycle.
These patients were considered treatment failures in the
response analysis. Thus, 50 patients were evaluable for
response and 47, for toxicity analysis. The patients’ demo-
graphics are shown in Table 1.
The 53 eligible patients received a total of 264 admin-
istrations of cisplatin, with the median being 6/patient
(range 0 –6/patient). Reasons why the six planned cisplatin
administrations were not completed are shown in Table 2.
Treatment delays of 1 week in 14 patients and of 2 weeks in
7 patients were necessary because of slow recovery of
leukocytes and/or platelets. With the exception of the
patient who developed neutropenic fever, leuko- and throm-
bocytopenia were not observed before the third cisplatin
administration. Of the 35 patients who completed the
planned treatment, 17 reached the planned cisplatin dose
intensity of 60 mg/m2 per week; 11 patients treated with a
1-week delay reached a dose intensity of 52.5 mg/m2 per
week; and 7 patients treated with a 2-week delay achieved a
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Table 1mPatients’ characteristics
Eligible patients (n) 53
M: F 40 : 13
















Large-cell undifferentiated carcinoma 8
dose intensity of 47 mg/m2 per week. In all, 31 patients
continued taking oral etoposide after the first response
evaluation: 1 patient for 1 course, 10 patients for 2 courses,
4 patients for 3 courses, and 15 patients for the full
4 courses. In 14 cases, etoposide cycles were delayed
once or twice for 1 week because of leukocytopenia.
Response
Of the 22 patients with stage III disease, 21 were evaluable
for response; 1 patient was not evaluable because of
concomitant radiotherapy. In eight stage III patients the
response was not confirmed after 4 weeks because of
additional surgery or radiotherapy. Five patients with
stage III a tumors were included in this study: in two
patients the tumors were considered initially too large for
surgery, two patients were considered inoperable for med-
ical reasons, and one patient refused surgery. All five
patients with stage III a tumors responded, and two patients
underwent a pneumonectomy. Both of the latter patients
had viable tumor in the surgical specimen; one patient died
of respiratory failure postoperatively and the other patient is
alive and free of disease at 220-weeks. Two patients had
radiotherapy but their disease relapsed at 21 and 36 weeks,
respectively, and one patient refused further treatment. Of
the 17 stage III b patients, 13 completed treatment and 6 had
a partial response. Including as treatment failures the four
patients who refused or did not complete treatment due to
toxicity the overall response rate in stage III disease was
52% (95% confidence interval 32– 77%) as opposed to only
35% in patients with stage III b disease (95% confidence
interval 20 –54%). Four stage III b patients did not continue
taking oral etoposide because of radiotherapy. The other
patients were continued on oral etoposide. The overall
median duration of survival for all stage III patients was
48 weeks (range 7 – 220-weeks); the median duration of
survival for the subgroup of III b patients was 34 weeks
(range 27– 61 weeks).
Of the 31 patients with stage IV disease, 29 were
evaluable for response. Two patients were not evaluable:
one patient never started treatment and one patient received
too low a cisplatin dose. Nine patients showed a partial
response (32%; 95% confidence interval 15– 49%) with a
median duration of 28 weeks (range 16 –44 weeks). In all,
12 patients showed stable disease with a median duration of
18 weeks (range 12 – 32 weeks). The median overall dura-
tion of survival for stage IV patients was 45 weeks (range
26– 106 weeks). The chance of achieving a response was
equal for the histologic subtypes; of 21 evaluable patients
with squamous-cell carcinoma, 12 showed a response
versus 6/18 patients with adenocarcinoma and 2/7 patients
with large-cell undifferentiated carcinoma (P = 0.29;
Fisher’s exact test). None of the patients with a perfor-
mance status of 2 (all of whom had metastatic disease)
responded.
Toxicity
The toxicity data are summarized in Table 3. The worst
toxicity per patient observed over the whole treatment
period is shown according to WHO grade. For ototoxicity
the Common Toxicity Criteria (CTC) grading scale was
used [27]. Anemia was universal, with 38 patients devel-
oping
4grade 1 anemia. A total of 30 patients required
packed-red-cell transfusions for a total of 127 units. Grade
3+4 leukocytopenia was observed in 17 patients. Leukocy-
topenia was the main cause of treatment delay, mainly
occurring on day 29, when the fourth cisplatin administra-
tion was planned. Only one patient developed neutropenic
fever. There was no toxic death. Thrombocytopenia of
grade 3 was observed in six patients and that of grade 4,
in two patients. One patient required a platelet transfusion
on one occasion. No hemorrhagic complication was ob-
served.
All patients developed alopecia; nausea and vomiting
was seldom observed during the first 3 weeks of the
treatment but occurred frequently thereafter and was also
frequently reported during the oral etoposide maintenance
phase. A total of 20 patients lost 45% of their initial body
weight, and 5 of these patients showed a weight loss of
410%. Nephrotoxicity was limited to grade 1 in seven
patients. With the exception of the patient who developed
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Table 3mToxicity according to WHO grade: worst toxicity per patient
(CTC Common Toxicity Criteria)
Toxicity WHO grade
0 1 2 3 4
Anemia 0 9 31 7 0
WBC 4 12 14 13 4
Platelets 13 19 7 6 2
Nephrotoxicity 40 7 0 0 0
Neurotoxicity 33 13 0 0 1a
Ototoxicity (CTC) 25 8 12 2 0
a Patient with reversible cortical blindness





0 1 patient Never started
1 3 patients Refusal 1, irradiation on indicator
lesion 1, early PD 1
2 2 patients Neutropenic fever 1, ototoxicity 1
3 6 patients PD 3, cardiac death 1,
ototoxicity 1, 42-week delay 1
4 1 patient Refusal
5 5 patients PD 2, cerebral toxicity 1,
42-week delay 1, erysipelas 1
6 35 patients –
reversible cortical blindness, neurotoxicity was limited to
grade 1 in 13 patients. In all, 2 patients reported clinical
hearing loss (CTC grade 3) and 12 patients, tinnitus
(ototoxicity of grade 2). Hypomagnesemia of 50.55
mmol/l was observed in ten patients. One patient developed
seizures after the sixth cisplatin administration, showing a
magnesium level of 0.23 mmol/l.
Discussion
Numerous phase II and III studies have been performed in
NSCLC over the last two decades and, nevertheless the
discussion on “the best” regimen continues. The combina-
tion of cisplatin and etoposide is frequently used, and the
response rate averages 30% [22]. Studies analyzing the
results obtained in locally advanced disease separately
report even higher response rates of up to 69% in this
subset of patients [39].
Retrospective analyses of several tumor types have
suggested that the dose intensity of chemotherapy may be
important [8, 20]. However, the results of prospective
randomized studies addressing cisplatin dose intensity in
NSCLC are inconclusive. The first study was reported in
1981 by Gralla et al. [16]. In this study cisplatin at 120 mg/
m2 was compared with cisplatin at 60 mg/m2, given every
4 weeks in combination with vindesine. The response rate
was equal in the two arms (43%), but the response duration
was superior in the high-dose arm as compared with the
low-dose arm (12 versus 5.5 months) and the median
survival of responders in the high-dose arm was more
than double that of responders in the low-dose arm [16].
Klastersky et al. [23] compared cisplatin given at 120
versus 60 mg/m2 in combination with etoposide every
3 – 4 weeks and observed no difference in response rate or
survival between the two treatment arms.
In the three-arm study of Gandara et al. [14], cisplatin
given as a single agent at 50 mg/m2 on days 1 and 8 every
4 weeks was compared with single-agent high-dose cispla-
tin given at 100 mg/m2 on days 1 and 8 versus cisplatin
given at 100 mg/m2 on days 1 and 8 plus mitomycin C
given at 8 mg/m2 on day 1 every 4 weeks. Only stage IV
patients were included in this study. A response was
observed in 12% of patients in the standard-dose arm and
in 14% of those in the high-dose single-agent-cisplatin arm.
In the high-dose arm with mitomycin C the response rate
was 27%. Complete responders were observed only in the
high-dose arms. Survival, however, did not differ between
the treatment arms. The highest cisplatin dose intensity
reached in these studies was 41 mg/m2 per week [14].
In a phase 1 study we have shown that with weekly
administration of cisplatin a higher cisplatin dose intensity
can be reached [33]. Weekly administration of chemother-
apy also has the theoretical advantage that regrowth of
sublethally damaged tumor cells should be hindered more
effectively than in schedules with longer intervals. Studies
performed in the 1970s with weekly administration of
cisplatin showed activity in NSCLC and head and neck
cancer but were not explored further because of toxicity [5,
34, 40]. With improved supportive measures, weekly ad-
ministration of cisplatin has become feasible, which the
present study again confirms: most patients reached a
cisplatin dose intensity of 52.5– 60 mg/m2 per week, and
we observed a response in 32% of patients with stage IV
disease and in 52% of those with stage III disease. This
response rate is comparable with that reported for other
“high-ranking” regimens [6, 39].
Also as compared with other studies using frequent
dosing of cisplatin in NSCLC, the dose intensity we
achieved was high. Higano et al. [18] used cisplatin weekly
at a dose of 50 mg/m2 in combination with mitomycin C,
vinblastine, and fluorouracil and reported a response in
23% of their patients, but these included only patients with
distant metastases. The median dose intensity of cisplatin
reached in their study was 40– 44 mg/m2 per week [18].
O’Dwyer et al. [30] reported a phase II study of weekly
cisplatin given at a dose of 30 mg/m2 in combination with
weekly 24-h infusions of fluorouracil and vinblastine. In all,
44% of their patients responded; however, the median
duration of response was only 4 months [30].
In general, the toxicity of our regimen was acceptable.
Only one patient had neutropenic fever; there was no toxic
death. Leukocytopenia and, to a lesser degree, thrombocy-
topenia were the most frequent causes of treatment delay,
partly jeopardizing the dose-intensity concept. Only seven
patients developed renal toxicity of grade 1; this low
number may be related to the administration of cisplatin
in hypertonic saline and to the vigorous hydration program.
In Higano et al.’s study [18], which also involved cisplatin
administration in hypertonic saline, renal toxicity of grade 2
and higher was observed in only 6 of 77 patients. These
results contrast with those of Vogl et al. [40], who reported
renal toxicity in 40% of 30 patients treated with cisplatin at
75 mg/m2 on days 1, 8, 15 and every 3 weeks thereafter,
with cisplatin being infused in dextrose-saline.
In all, 13 patients in our study developed neurotoxicity
of grade 1; no patient developed grade 2 neurotoxicity,
although most patients received a cumulative cisplatin dose
of 420 mg/m2. All these patients were followed for
6 months, if possible, as it is known that neurotoxic signs
may even worsen after the cessation of treatment [19].
Cortical blindness is a very seldom-reported manifestation
of cisplatin neurotoxicity; a relationship to hypomagnese-
mia has been suggested [15]. Hypomagnesemia can lead to
focal or generalized seizures, as we observed in another
patient. However, on the day of visual loss, our patient had
a normal serum magnesium level; he recovered completely.
Ototoxicity of grade 2+3 was observed in 28% of our
patients; this toxicity is common to high-dose cisplatin
regimens. Kim et al. [21] used cisplatin at 180 mg/m2
every 2 weeks in combination with sodium thiosulfate,
thereby achieving a median cisplatin dose intensity of
79 mg/m2 per week, and reported the development of a
hearing loss in 9 of 19 patients. Gandara et al. [14] reported
a 17% incidence of ototoxicity in the high-dose cisplatin
arm of their study. As clinical hearing loss is irreversible, it
now replaces classic cisplatin-induced toxicities such as
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nephro- and gastrointestinal toxicity in being dose-limiting.
The response rate of 52% obtained in stage III disease, in
our opinion, warrants further exploration of the present
regimen in locally advanced NSCLC, and its combination
with radiotherapy might be attractive provided that toxicity
can be limited. Recently the Radiation Therapy Oncology
Group [24] reported a study of cisplatin given at 50 mg/m2
on days 1 and 8 in combination with oral etoposide given at
75 or 100 mg/day on days 1 –14 with concomitant hyper-
fractionated radiotherapy. The response rate of 70% was
encouraging, but the toxicity, especially hematologic tox-
icity and esophagitis, was high [24]. Combination with
chemoprotective agents (such as WR-2721 or sodium
thiosulfate) could be of interest for these high-dose sche-
dules. If they indeed have a protective effect against
toxicity, randomized studies comparing highly dose-inten-
sive regimens with standard-dose regimens in larger patient
populations or their combination with radiotherapy would
become possible. However, in our opinion, equal treatment
results can be achieved in stage IV disease with less intense
regimens.
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